Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
暂无分享,去创建一个
Deepak L. Bhatt | Deepak L Bhatt | Lawrence A Leiter | E. Braunwald | B. Scirica | D. McGuire | P. Steg | J. Udell | J. Nicolau | I. Raz | J. Davidson | R. Frederich | R. Corbalán | Boaz Hirshberg | Eugene Braunwald | Itamar Raz | Darren K McGuire | Ph Gabriel Steg | Jacob A Udell | Jose C Nicolau | B. Hirshberg | Benjamin M Scirica | Jaime A Davidson | Matthew A Cavender | KyungAh Im | Ofri Mosenzon | M. Cavender | Ofri Mosenzon | Robert Frederich | Ramon Corbalan | A. Umez-Eronini | Amarachi A Umez-Eronini | Ping He | K. Im | Ping He
[1] H. Heinzl,et al. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. , 1997, Computer methods and programs in biomedicine.
[2] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[4] A. Skene,et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.
[5] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.
[6] Deepak L. Bhatt,et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial , 2013, Diabetes/metabolism research and reviews.
[7] S. Del Prato,et al. Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes , 2009, Diabetes Care.
[8] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[9] D. Cryer,et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. , 2005, Diabetes care.
[10] Deepak L. Bhatt,et al. Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus , 2012, Clinical cardiology.
[11] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[12] Keith C. Norris,et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. , 2008, American heart journal.
[13] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[14] Deepak L. Bhatt,et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.
[15] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[16] P. Sarafidis,et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] M. Kuro-o,et al. The emerging role of Klotho in clinical nephrology. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[19] A. Murray,et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.
[20] Darren K Mcguire,et al. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. , 2008, Circulation.
[21] W. Herrington,et al. Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease? , 2011, Nephron Clinical Practice.
[22] Markolf Hanefeld,et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.
[23] I. Raz,et al. Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No , 2009, Diabetes Care.
[24] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.
[25] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[26] S. Inzucchi,et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.
[27] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[28] T. Wilt,et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] H. Yokoyama,et al. Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study , 2011, Clinical and Experimental Nephrology.
[30] R. Simon,et al. Flexible regression models with cubic splines. , 1989, Statistics in medicine.
[31] K. Lipska,et al. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.
[32] Marcello Tonelli,et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.
[33] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[34] F. Wolf. Standards of Medical Care in Diabetes—2014 , 2013, Diabetes Care.
[35] A. Collins,et al. Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.
[36] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[37] M. Nowicki,et al. Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study , 2011, International journal of clinical practice.
[39] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[40] D. Boulton,et al. Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin , 2011, Clinical pharmacokinetics.
[41] M. Woodward,et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] L. Schiöler,et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register , 2012, BMJ Open.
[43] Deepak L. Bhatt,et al. Metformin use and mortality among patients with diabetes and atherothrombosis. , 2010, Archives of internal medicine.
[44] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.